Profile data is unavailable for this security.
About the company
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
- Revenue in EUR (TTM)153.71m
- Net income in EUR-101.43m
- Incorporated1999
- Employees684.00
- LocationValneva SE6 rue Alain BombardSAINT-HERBLAIN 44800FranceFRA
- Phone+33 228073710
- Fax+33 144217078
- Websitehttps://valneva.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Euroapi SA | 1.02bn | -189.70m | 255.31m | 3.67k | -- | 0.2746 | -- | 0.2506 | -2.01 | -2.01 | 10.73 | 9.78 | 0.6086 | 1.38 | 4.24 | 277,705.10 | -11.34 | -- | -15.93 | -- | 16.15 | -- | -18.63 | -- | 0.6573 | -- | 0.1955 | -- | 3.87 | -- | -1,164.67 | -- | -- | -- |
| Nanobiotix SA | 0.00 | -58.78m | 260.88m | 101.00 | -- | -- | -- | -- | -1.68 | -1.68 | 0.00 | -1.53 | 0.00 | -- | -- | 0.00 | -97.14 | -55.16 | -411.11 | -75.16 | -- | -- | -- | -89,710.66 | -- | -6.62 | -- | -- | -100.00 | -- | -21.36 | -- | -42.16 | -- |
| Carbios SA | 24.00k | -27.22m | 347.86m | 134.00 | -- | 1.48 | -- | 14,494.26 | -2.03 | -2.03 | 0.0017 | 13.92 | 0.0001 | -- | 0.7619 | 179.10 | -11.20 | -9.92 | -12.13 | -10.77 | -- | -- | -113,433.30 | -3,365.22 | 9.43 | -- | 0.1552 | -- | -65.71 | -53.32 | 1.86 | -- | 141.01 | -- |
| Medincell SA | 10.85m | -26.42m | 351.76m | 138.00 | -- | -- | -- | 32.43 | -1.02 | -1.02 | 0.4086 | -0.8965 | 0.2605 | -- | 6.81 | 75,853.15 | -63.46 | -59.54 | -115.15 | -117.36 | 60.43 | 68.38 | -243.58 | -451.26 | -- | -4.29 | 1.69 | -- | 141.78 | 8.96 | -29.04 | -- | -2.87 | -- |
| Guerbet SA | 785.69m | 23.87m | 448.76m | 2.92k | 19.74 | 1.18 | 5.39 | 0.5712 | 1.80 | 1.80 | 62.15 | 29.97 | 0.7997 | 0.5983 | 5.80 | 269,071.90 | 2.26 | 1.40 | 2.96 | 1.86 | 78.01 | 76.02 | 2.82 | 1.82 | 1.21 | 5.62 | 0.5035 | 57.82 | 4.30 | -0.0993 | 158.05 | -12.61 | 5.23 | -10.07 |
| Valneva SE | 153.71m | -101.43m | 499.73m | 684.00 | -- | 3.88 | -- | 3.25 | -0.7343 | -0.7343 | 1.11 | 0.924 | 0.2843 | 2.54 | 4.69 | 224,726.60 | -18.76 | -15.39 | -31.44 | -25.06 | 34.37 | 35.94 | -65.99 | -34.95 | 1.37 | -3.57 | 0.6195 | -- | -57.46 | 6.34 | 29.21 | -- | 35.18 | -- |
| Boiron SA | 517.36m | 47.62m | 596.54m | 2.81k | 12.40 | 1.07 | 9.03 | 1.15 | 2.74 | 2.74 | 29.79 | 31.73 | 0.6792 | 1.36 | 6.57 | 184,705.80 | 6.14 | 5.08 | 7.56 | 6.39 | 73.88 | 75.12 | 9.04 | 7.40 | 2.54 | -- | 0.0225 | 48.87 | 17.36 | -2.86 | 56.44 | -10.60 | -19.01 | -7.22 |
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 10 Apr 2024 | 6.93m | 4.99% |
| Polar Capital LLPas of 29 Feb 2024 | 5.02m | 3.61% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 3.58m | 2.58% |
| CDC Croissance SAas of 15 Nov 2022 | 2.07m | 1.49% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 1.52m | 1.09% |
| Medical Strategy GmbHas of 29 Dec 2023 | 1.48m | 1.07% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.43m | 1.03% |
| Apo Asset Management GmbHas of 30 Sep 2023 | 672.32k | 0.48% |
| BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 435.05k | 0.31% |
| HSBC Global Asset Management (France) SAas of 29 Feb 2024 | 335.63k | 0.24% |
